GXI N Stock Overview

Manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally. More details

GXI N fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	3/6
Past Performance	4/6
Financial Health	3/6
Dividends	3/6

Rewards

Trading at 4.7% below our estimate of its fair value

Earnings are forecast to grow 19.65% per year

Earnings grew by 20.8% over the past year

Risk Analysis

Shares are highly illiquid

Has a high level of debt

Shareholders have been diluted in the past year

My Notes

Capture your thoughts, links and company narrative

Gerresheimer AG Competitors

Genomma Lab Internacional. de

BMV:LAB B

Mex$25.2b

Syngene International

NSEI:SYNGENE

₹344.9b

SCHOTT Pharma KGaA

XTRA:1SXP

€3.6b

Sotera Health

NasdaqGS:SHC

US$3.7b

Price History & Performance

Summary of share price highs, lows and changes for Gerresheimer
Historical stock prices
Current Share Price	€1,649.75
52 Week High	€1,649.75
52 Week Low	€1,649.75
Beta	0.91
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent updates

Shareholder Returns

	GXI N	MX Life Sciences	MX Market
7D	0%	0%	0%
1Y	n/a	0%	0%

Return vs Industry: Insufficient data to determine how GXI N performed against the MX Life Sciences industry.

Return vs Market: Insufficient data to determine how GXI N performed against the MX Market.

Price Volatility

Is GXI N's price volatile compared to industry and market?
GXI N volatility
GXI N Average Weekly Movement	n/a
Life Sciences Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stable Share Price: GXI N has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine GXI N's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1864	11,660	Dietmar Siemssen	www.gerresheimer.com

Gerresheimer AG, together with its subsidiaries, manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally. It operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The company offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and glass bottles and jars, as well as caps, closures, applicators, and accessories; development, industrialization and contract manufacturing of drug delivery programs; project and quality management; and drug delivery systems, including inhalers, injection/auto injectors, pen injectors, infusion systems, and inhalation assessment, autoinjector, and other services.

Gerresheimer AG Fundamentals Summary

How do Gerresheimer's earnings and revenue compare to its market cap?
GXI N fundamental statistics
Market cap	Mex$66.10b
Earnings (TTM)	Mex$2.11b
Revenue (TTM)	Mex$36.21b

31.3x

P/E Ratio

1.8x

P/S Ratio

Is GXI N overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GXI N income statement (TTM)
Revenue	€1.99b
Cost of Revenue	€1.39b
Gross Profit	€597.31m
Other Expenses	€481.19m
Earnings	€116.13m

Last Reported Earnings

Nov 30, 2023

Next Earnings Date

Apr 11, 2024

Earnings per share (EPS)	3.36
Gross Margin	30.01%
Net Profit Margin	5.83%
Debt/Equity Ratio	66.5%

How did GXI N perform over the long term?

See historical performance and comparison

Dividends

1.2%

Current Dividend Yield

36%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/03/16 12:36
End of Day Share Price	2023/12/18 00:00
Earnings	2023/11/30
Annual Earnings	2023/11/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Gerresheimer AG is covered by 35 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Gaurav Jain	Barclays
Victoria Lambert	Berenberg
Scott Bardo	Berenberg

Gerresheimer BMV:GXI N Stock Report